Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
570 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04025879 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 461 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | active not recruiting | Phase 3 | 605 | Daiichi Sankyo |
| 26 |
| Aug 26, 2026 |
| clinicaltrials |
| NCT05456191 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)(ASC4START) | active not recruiting | Phase 3 | 568 | Novartis PharmaceuticalsINDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT05722015 | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) | active not recruiting | Phase 3 | 377 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Aug 26, 2026 | clinicaltrials |
| NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection(REZILIENT4) | active not recruiting | Phase 3 | 360 | Taiho Oncology, Inc.INDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT04039607 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma(CheckMate 9DW) | completed | Phase 3 | 732 | Bristol-Myers SquibbINDUSTRY | 26 | Aug 25, 2026 | clinicaltrials |
| NCT03141177 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER) | completed | Phase 3 | 701 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 24, 2026 | clinicaltrials |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). | terminated | Phase 3 | 863 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 21, 2026 | clinicaltrials |
| NCT04008030 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)(CheckMate 8HW) | active not recruiting | Phase 3 | 839 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 20, 2026 | clinicaltrials |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy(CAMBRIA-1) | recruiting | Phase 3 | 4,300 | AstraZenecaINDUSTRY | 39 | Aug 19, 2026 | clinicaltrials |
| NCT03106779 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | completed | Phase 3 | 233 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 18, 2026 | clinicaltrials |
| NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | active not recruiting | Phase 3 | 1,854 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Aug 14, 2026 | clinicaltrials |
| NCT06713837 | IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.(IMPACT-AML) | recruiting | Phase 3 | 339 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 7 | Aug 14, 2026 | clinicaltrials |
| NCT04603807 | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | active not recruiting | Phase 3 | 217 | Hoffmann-La RocheINDUSTRY | 18 | Aug 13, 2026 | clinicaltrials |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-01) | active not recruiting | Phase 3 | 510 | Olema Pharmaceuticals, Inc.INDUSTRY | 26 | Aug 13, 2026 | clinicaltrials |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04) | recruiting | Phase 3 | 695 | Gilead SciencesINDUSTRY | 23 | Aug 12, 2026 | clinicaltrials |
| NCT01437787 | Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis(JAKARTA) | terminated | Phase 3 | 289 | Bristol-Myers SquibbINDUSTRY | 25 | Aug 11, 2026 | clinicaltrials |
| NCT04685135 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation(KRYSTAL-12) | active not recruiting | Phase 3 | 453 | Mirati Therapeutics Inc.INDUSTRY | 24 | Aug 11, 2026 | clinicaltrials |
| NCT05303532 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab(ROSY-D) | enrolling by invitation | Phase 3 | 214 | AstraZenecaINDUSTRY | 31 | Aug 11, 2026 | clinicaltrials |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)(CAMBRIA-2) | active not recruiting | Phase 3 | 5,511 | AstraZenecaINDUSTRY | 44 | Aug 10, 2026 | clinicaltrials |
| NCT06298552 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis(ADAPT SERON) | active not recruiting | Phase 3 | 119 | argenxINDUSTRY | 22 | Aug 10, 2026 | clinicaltrials |
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 3 | 726 | Daiichi SankyoINDUSTRY | 26 | Aug 10, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT03706365 | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer(CYCLONE 2) | active not recruiting | Phase 2 / Phase 3 | 393 | Eli Lilly and CompanyINDUSTRY | 11 | Aug 7, 2026 | clinicaltrials |
| NCT04099251 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma(CheckMate76K) | active not recruiting | Phase 3 | 790 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 7, 2026 | clinicaltrials |
| NCT02542293 | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)(NEPTUNE) | active not recruiting | Phase 3 | 953 | AstraZenecaINDUSTRY | 29 | Aug 6, 2026 | clinicaltrials |
| NCT05232916 | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects(FLAMINGO-01) | recruiting | Phase 3 | 2,250 | Greenwich LifeSciences, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | recruiting | Phase 2 / Phase 3 | 312 | Moleculin Biotech, Inc.INDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma(EPCORE™FL-2) | active not recruiting | Phase 3 | 1,095 | GenmabINDUSTRY | 32 | Aug 4, 2026 | clinicaltrials |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | recruiting | Phase 3 | 510 | Daiichi SankyoINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation(CheckMate 9DX) | active not recruiting | Phase 3 | 545 | Bristol-Myers SquibbINDUSTRY | 25 | Jul 31, 2026 | clinicaltrials |
| NCT05876754 | An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma(ProvIDHe) | active not recruiting | Phase 3 | 299 | Servier Affaires MédicalesINDUSTRY | 16 | Jul 31, 2026 | clinicaltrials |
| NCT02632409 | An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer(CheckMate 274) | completed | Phase 3 | 709 | Bristol-Myers SquibbINDUSTRY | 30 | Jul 30, 2026 | clinicaltrials |
| NCT04784715 | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | active not recruiting | Phase 3 | 1,157 | AstraZenecaINDUSTRY | 27 | Jul 30, 2026 | clinicaltrials |
| NCT05973773 | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)(REZILIENT3) | active not recruiting | Phase 3 | 285 | Taiho Oncology, Inc.INDUSTRY | 23 | Jul 30, 2026 | clinicaltrials |
| NCT07039916 | Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | recruiting | Phase 3 | 231 | Immunovant Sciences GmbHINDUSTRY | 15 | Jul 30, 2026 | clinicaltrials |
| NCT02486718 | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] | active not recruiting | Phase 3 | 1,280 | Hoffmann-La RocheINDUSTRY | 21 | Jul 29, 2026 | clinicaltrials |
| NCT03425643 | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | active not recruiting | Phase 3 | 797 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Jul 29, 2026 | clinicaltrials |
| NCT07106762 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 29, 2026 | clinicaltrials |
| NCT05050942 | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET(SORENTO) | active not recruiting | Phase 3 | 332 | Camurus ABINDUSTRY | 12 | Jul 28, 2026 | clinicaltrials |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study(IMbrella B) | active not recruiting | Phase 3 | 1,000 | Hoffmann-La RocheINDUSTRY | 24 | Jul 24, 2026 | clinicaltrials |
| NCT06012435 | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 762 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Jul 23, 2026 | clinicaltrials |
| NCT06472245 | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor(ARTEMIA) | recruiting | Phase 3 | 363 | OSE ImmunotherapeuticsINDUSTRY | 14 | Jul 23, 2026 | clinicaltrials |
| NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | completed | Phase 3 | 703 | Merck Sharp & Dohme LLCINDUSTRY | 27 | Jul 22, 2026 | clinicaltrials |
| NCT04895358 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | active not recruiting | Phase 3 | 342 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Jul 22, 2026 | clinicaltrials |
| NCT01933932 | Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC(SELECT-1) | active not recruiting | Phase 3 | 510 | AstraZenecaINDUSTRY | 26 | Jul 21, 2026 | clinicaltrials |
| NCT06698042 | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | active not recruiting | Phase 3 | 67 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Jul 21, 2026 | clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials